LC
EFTR

Littlejohn & Co’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Littlejohn & Co’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,000
Closed -$495K – 212
2021
Q2 		$495K Buy
+2,000
New +$492K 0.15% 58

Other funds holding EFTR

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Littlejohn & Co's EFTR Position: Q3 2021 in Review

Littlejohn & Co sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2021, closing a stake of 2,000 shares — an estimated $495K sold.

Littlejohn & Co first reported a position in EFTR in Q2 2021 and held it in 1 quarter. The position peaked at $495K in Q2 2021. 12 funds tracked by Wall St. Rank hold EFTR as of Q3 2021.

  • Littlejohn & Co reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Littlejohn & Co sold 2,000 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $495K.
  • Littlejohn & Co first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Littlejohn & Co's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $495K in Q2 2021.
  • 12 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Littlejohn & Co's 13F filing for Q3 2021, filed 12 Nov 2021.